ROR1-Targeting PET Ligand Preclinical Evaluation for Melanoma

Figshare hosts data from a preclinical study evaluating four peptide-based PET ligands ([68Ga]1-4) for imaging the ROR1 receptor in melanoma. The dataset contains results from in vitro binding assays and microPET/CT imaging in three mouse tumor models (B16F10, A375, SK-MEL-28), highlighting ligand [68Ga]2 for its high tumor accumulation (9.18% ID/g). Author Donglan Huang published the supporting data under a CC BY-NC 4.0 license in 2026.

Use Cases

• Analyze the ROR1 binding affinity (KD values) of ligands [68Ga]2 and [68Ga]3 from in vitro assay data.
• Compare tumor accumulation (% ID/g) and background signal across ligands [68Ga]1-4 using microPET/CT imaging results.
• Evaluate specific cellular uptake data for albumin-binding ligands [68Ga]2 and [68Ga]3 in melanoma cell lines.
• Correlate imaging performance metrics with ligand structural features from the design rationale for probe optimization.

Strengths

• Data supports a 2026 publication, indicating recent preclinical research.
• Includes quantitative results from three distinct mouse tumor models (B16F10, A375, SK-MEL-28).
• Reports specific, high-value metrics like tumor accumulation up to 9.18% ID/g and binding affinities (KD = 44.9 nM).

Limitations

• The dataset is very small (1.6 KB), suggesting it contains summary results, not raw experimental measurements.
• Data scope is limited to four specific ligands ([68Ga]1-4) and three melanoma cell lines, not a broad screening.
• As preclinical animal model data, direct applicability to human clinical contexts is uncertain.

Provenance

Source

Figshare, authored by Donglan Huang.

Collection Method

Preclinical laboratory evaluation including in vitro assays and in vivo microPET/CT imaging in mice.

Freshness

Last updated in March 2026.